Highlights CorMedix Inc.

Stocks

CRMD

US21900C3088

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2026 am IST			5-day change	1st Jan Change
8.420 ^USD	+1.57%		+0.24%	-27.60%

07/07	RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating	MT
03/07	CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer	MT

Highlights

14/05	CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
14/05	Tranche Update on CorMedix Inc.'s Equity Buyback Plan announced on February 2, 2026.	CI
14/05	CorMedix Therapeutics Raises Earnings Guidance for the Full-Year 2026	CI
27/04	Cormedix Therapeutics Announces Positive Topline Results from Phase III Respect Trial Assessing Rezzayo for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients	CI
06/03	CorMedix Shares Fall After Q4 Profit Miss	MT
05/03	CorMedix Inc. Reiterates Earnings Guidance for the Year 2026	CI
05/03	CorMedix Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02/02	CorMedix Authorizes Up to $75 Million Stock Buyback; Shares Rise	MT
02/02	CorMedix Inc. announces an Equity Buyback for $75 million worth of its shares.	CI
02/02	CorMedix Inc. authorizes a Buyback Plan.	CI
08/01	CorMedix Inc. Provides Earnings Guidance for the Year 2026	CI
08/01	CorMedix Reports Q4 Preliminary Net Revenue, Provides Guidance; Names CEO Joseph Todisco Chairman	MT
08/01	Cormedix Therapeutics announces preliminary fourth quarter and full year 2025 results	RE
08/01	(CRMD) CorMedix Expects 2026 Revenue Range $300M to $320M, vs. FactSet Est of $435.7	MT
08/01	Earnings Flash (CRMD) CorMedix Posts Q4 Preliminary Net Revenue $127M, vs. FactSet Est of $128.3M	MT
18/12	Cormedix Therapeutics Announces Positive Data from Ongoing Real World Evidence Study of Defencath	CI
12/11	CorMedix Inc. Raises Earnings Guidance for the Year Ending December 31, 2025	CI
12/11	CorMedix Inc. Provides Earnings Guidance for the Fourth Quarter Ended December 31, 2025	CI
12/11	CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/11	CorMedix Swings to Q3 Profit, Revenue Rises; Lifts Full-Year Guidance	MT
12/11	Biopharma firm CorMedix's Q3 net income beats expectations	RE
12/11	Earnings Flash (CRMD) CorMedix Posts Q3 EPS $1.26, vs. FactSet Est of $0.95	MT
12/11	(CRMD) CorMedix Inc. Expects Q4 Revenue Range $115.0M - $135.0M	MT
12/11	Earnings Flash (CRMD) CorMedix Inc. Reports Q3 Revenue $104.3M, vs. FactSet Est of $86.0M	MT
20/25/20	CorMedix Reports Q3 Preliminary Net Revenue; Lifts Full-Year Net Revenue Guidance	MT